GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

GlaxoSmithKline’s shingles vaccine Shingrix shot out of the gate after its 2017 launch and performed so well that the drugmaker eventually ran into supply shortages due to higher-than-expected demand.

More recently, though, the COVID-19 pandemic put the brake on routine healthcare visits for most Americans. That’s led to a drop-off in vaccinations, which gave GSK some time to catch up on production. The company has produced “without interruption” during the pandemic, a spokesman said.